MENU
MAY 02, 2017 8:00 AM PDT

Counteracting tumor evasion of antibody immunity, free webinar and Q&A session

Sponsored by: Abcam
Speaker
  • Professor of Molecular Medicine, Robert A. Welch Distinguished University Chair in Chemistry; Director, Texas Therapeutics Institute University of Texas Health Science Center at Houston
    BIOGRAPHY

Abstract

DATE: May 2, 2017
TIME: 8:00am PT, 11:00am ET, 4:00pm GMT, 5:00pm CET

The natural immune responses that patients develop to their own tumors, as well as therapeutic regimens employing the latest anti-cancer monoclonal antibodies, would reasonably be expected to suppress tumor growth. Yet, a perplexing resistance to both is widespread. The ineffectiveness of the immune system to prevail in these situations suggests that cancers possess tactics to evade antibodies that could otherwise eradicate them. 

With a clinical context in mind, we observed that tumor-associated protein-degrading enzymes can diminish, and in some cases negate, cell killing functions by inducing a single clip in a small part of the antibody structure. The structural modification is so subtle that it had not been previously recognized and would not have been anticipated to so profoundly impair the antibody. To be able to visualize and establish if such cleavage occurred in cancer, we had to develop innovative antibodies for that exact purpose. 

The new antibodies readily enabled the visualization of antibody damage when incubated with cancer cells in the laboratory or within tumor tissues obtained from animals or human patients - more importantly - the same antibody tools possessed the additional and remarkable property of restoring the lost functions to the damaged antibodies. The “rescue” of lost function suggested that this could be exploited as a therapy in cases where tumors cause antibody damage in order to evade our immune system. This novel therapeutic strategy represents a potentially new direction in cancer immunotherapy.

This webinar will review:

  • A minor proteolytic cleavage at IgG hinge greatly impairs the effector functions of anticancer antibodies
  • Proteolytic hinge cleavage of IgGs as a mechanism of tumor evasion of antibody-based immunity
  • The potential of “rescue” of lost IgG Fc function as a novel therapeutic strategy for cancer

Learning Objectives:

  • Review mechanisms of tumor cells used to evade interaction from anti-cancer antibodies 
  • Learn how antibody technology can be used to develop antibodies capable of visualizing subtle, specific modifications
  • Learn about a potential novel cancer therapeutic method of ‘’restoring’’ antibodies damaged by tumor-associated protein-degrading enzymes

Show Resources
You May Also Like
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
SEP 22, 2022 9:00 AM PDT
SEP 22, 2022 9:00 AM PDT
Date: September 22, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarke...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
JUN 22, 2022 10:00 AM PDT
JUN 22, 2022 10:00 AM PDT
Date: June 22, 2022 Time: 10:00am (PDT), 1:00pm (EDT), 7:00pm (CEST) Rabbits have a robust and unique immune system that enables the generated antibodies with superior specificity, affinity,...
OCT 11, 2022 8:00 AM PDT
C.E. CREDITS
OCT 11, 2022 8:00 AM PDT
Date: October 11, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Multiomic profiling of cell populations at single-cell resolution is revolutionizing scientists’ understanding o...
MAY 02, 2017 8:00 AM PDT

Counteracting tumor evasion of antibody immunity, free webinar and Q&A session

Sponsored by: Abcam


Show Resources
Loading Comments...
Show Resources